Latest Reimbursement News

Microba Life Sciences reported robust Q3 FY25 growth in its microbiome diagnostic tests, led by MetaXplore and MetaPanel, while advancing its therapeutics pipeline and projecting strong full-year revenue growth.

PainChek Limited reports strong progress toward FDA De Novo clearance for US market entry, launches its Infant App in Australia, and achieves robust global licence growth with a 30% year-on-year revenue increase.

ImpediMed Limited reported a record A$3.4 million revenue in Q3 FY25, bolstered by a surge in Annual Recurring Revenue and a strategic sales leadership change aimed at accelerating SOZO platform adoption.

Cyclone Metals has inked a binding agreement with Vale S.A. for up to USD 138 million to develop its Iron Bear Project in Canada, marking a significant step forward with successful pilot production runs of high-grade iron concentrates and pellets.

Australian Mines Limited reports significant progress in its critical minerals projects during Q1 2025, capitalizing on geopolitical shifts that underscore the strategic importance of diversified supply chains. The company highlights expanded studies at Flemington and promising exploration results at Jequie and Resende, while navigating financing challenges for its Sconi nickel-cobalt asset.

Pacific Edge’s Cxbladder Plus and Triage 1 diagnostic tests are set for significant Medicare reimbursement increases, potentially reshaping the company’s US market prospects.

Echo IQ Limited marked a pivotal quarter with FDA clearance for EchoSolv AS, strategic US partnerships, and a clear path toward reimbursement and broader commercialisation.

Lumos Diagnostics reported a 21% quarter-on-quarter revenue increase in Q3 FY25, driven by strong product sales and expanded development agreements. The company also secured Medicare coverage in key US regions and advanced its pivotal FebriDx CLIA waiver study with FDA submission expected by year-end.

Aroa Biosurgery reports a second consecutive quarter of positive operating cash flow and record sales for its Myriad product line, while maintaining full-year FY25 revenue and EBITDA guidance.

Macarthur Minerals Limited reported a substantial loss of A$25.6 million for the nine months ending December 31, 2024, driven largely by the sale of its Hematite Project. Despite this setback, the company outlines plans for future funding and operational adjustments to sustain its business.

Artrya Limited has launched a A$15 million capital raising to fund the development and commercial rollout of its Salix AI-powered coronary artery disease diagnostic platform, targeting the lucrative US healthcare market.

Echo IQ has secured a $1.26 million refund under the Australian Government's R&D Tax Incentive, reinforcing its commitment to AI-driven solutions for structural heart disease detection.